July 1, 2002Current Opinion in Nephrology & Hypertension
Combination ACEI and ARB therapy: additional benefit in renoprotection?
Why the study?
Does combination ACEI and ARB therapy improve renoprotection compared to monotherapy in patients with chronic renal disease?
Population
Patients with diabetic nephropathy and non-diabetic forms of chronic renal disease, particularly those with…
Comparison
Combination therapy with angiotensin-converting… vs Monotherapy (ACEI or ARB alone).
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May enhance BP and proteinuria control with dual ACEI/ARB in CKD; leaves open confirmation of long-term renoprotection.
Structured PICO
Does combination ACEI and ARB therapy improve renoprotection compared to monotherapy in patients with chronic renal disease?
P
Population
Patients with diabetic nephropathy and non-diabetic forms of chronic renal disease, particularly those with continued hypertension or proteinuria despite angiotensin-converting enzyme inhibition.
I
Intervention
Combination therapy with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB).
C
Comparator
Monotherapy (ACEI or ARB alone).
O
Outcome
Renoprotection (antihypertensive and antiproteinuric effects).surrogate
Combination ACEI and ARB therapy may offer greater antihypertensive and antiproteinuric effects than monotherapy in chronic renal disease, though long-term studies are needed to confirm renoprotective potential.
Limitations
- relatively small patient numbers in clinical studies
- short follow-up periods in clinical studies
- experimental studies failed to distinguish clearly between additive antihypertensive effects and additive intrinsic renoprotective effects
Cite This Study
Taal et al. (2002) studied this question.